NCT04857866 is a Phase 1 clinical trial of XmAb27564 in Safety in Healthy Volunteers, sponsored by Xencor, Inc..

Who is sponsoring NCT04857866?

NCT04857866 is sponsored by Xencor, Inc..

What drugs are being tested in NCT04857866?

Interventions in NCT04857866: XmAb27564, Placebo.

What condition does NCT04857866 study?

NCT04857866 studies Safety in Healthy Volunteers.

Is NCT04857866 still recruiting?

NCT04857866 is currently completed. Last updated 1 March 2023.

Last reviewed 2023-03-01 · How we verify

NCT04857866

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

Completed Phase 1 Last updated 1 March 2023

What this trial tests

Phase 1 trial testing XmAb27564 in Safety in Healthy Volunteers in 48 participants. Completed in 10 November 2022.

Timeline

19 April 2021

Primary endpoint
10 November 2022

10 November 2022

Quick facts

Lead sponsor	Xencor, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	48
Start date	19 April 2021
Primary completion	10 November 2022
Estimated completion	10 November 2022
Sites	1 location across United States

Drugs / interventions tested

XmAb27564 — full drug profile →
Placebo

Conditions studied

Safety in Healthy Volunteers — all drugs for Safety in Healthy Volunteers →

Sponsor

Xencor, Inc. — full company profile →

Who can join

Adults 21 to 55, any sex, with Safety in Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of XmAb27564

Trials testing the same drug.

NCT06005792 — Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis · Phase 1 · terminated

Other Xencor, Inc. trials

Trials by the same sponsor.

NCT06173505 — Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced N · Phase 1, PHASE2 · terminated
NCT05996445 — A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors · Phase 1 · terminated
NCT05585034 — Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Adva · Phase 1 · completed
NCT06005792 — Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis · Phase 1 · terminated
NCT05032040 — A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04857866 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xencor, Inc.
Last refreshed: 1 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04857866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing